Risk Partners Life Sciences Roundtable 2024, thank you very much! Sign up now for the 26.06.2025 >

Cologne Higher Regional Court finally provides clarification with current ruling
in the area of D&O direct litigation

A new exciting ruling from the world of D&O insurance. The proceedings dealt with the question of who bears the burden of proof if a company does not first take action against the managing director in an internal liability case, but instead takes direct action against the D&O insurer(s) (so-called direct action). This is possible if the defendant has assigned his/her indemnification claims against the D&O insurer to the company. But what happens in this case to the privileged distribution of the burden of proof under section 93 (2) sentence 2 AktG? The Cologne Higher Regional Court has now provided some clarity here.

How is it basically?

In the normal case of an internal liability case, the managing director must prove that he/she has fulfilled his/her duty if he/she is sued by the company for damages for an alleged breach of duty. This benefits the suing company, as this is associated with hurdles in practice (keyword: documentation - see also our webinar with Fides Technology) . This applies in particular if the breach of duty was not (allegedly) committed recently, but years ago and now leads to a claim via the statutory subsequent liability. In legal terms and in practice, the company therefore enjoys a considerable privilege with regard to documentation standards in many companies when it comes to the distribution of the burden of proof under Section 93 (2) sentence 2 AktG.

What has now been decided?

The uncertainty was whether the company would have to demonstrate and prove the breach of duty in the event of a direct action against the D&O insurer(s), which would make such direct proceedings considerably more difficult. As a result, the company would follow in the footsteps of the directors and inherit their disadvantages in terms of the burden of proof. 

The Cologne judges have now clarified that the same rules apply in direct proceedings against the D&O insurer(s) as in "classic" directors' and officers' liability proceedings. This means that the insurer must prove that the insured manager has fulfilled his duties. The insurer therefore takes on the role of the manager. 

The ruling (case no. 9 U 206/22) fundamentally strengthens the position of companies that want to take direct action against their D&O insurers. It therefore becomes more attractive not to take legal action against the responsible managing director, but directly against his insurer. The prerequisite, however, is that the managing director assigns his insurance claim to the company beforehand or, in other words, also relinquishes control over the proceedings. In addition to the transfer of control by the managing director concerned, there are other issues to be considered, such as the effects specifically on public limited companies in the strict AG regime or disadvantages generally associated with the "direct action" with reference to insurance contractual obligations in the event of a claim, so that Risk Partners will continue to follow the developments surrounding the direct action intensively for our clients.  

Also read our other blog posts

Life Sciences

Atrialis GmbH - experts in clinical trial insurance

Atrialis GmbH - experts in clinical trial insurance & Risk Partners will play in the same team in the future. LifeSciences - Leading risk concepts for leading science! Under this guiding principle, we have been able to advise innovative companies from the biotechnology, pharmaceutical and medical device sectors comprehensively on risk issues for many years and support them with suitable insurance solutions in all growth and study phases, from foundation to IPO and beyond (e.g. insuring a clinical trial). Together with my team at Risk Partners GmbH, we would like to continue our focus, our passion

Read more "
Being Public

Whistleblower Protection Act

Whistleblower Protection Act ... is now in force. Hey #VCs, do you already have a system in place for safe #whistleblowing? And what about insurance cover in your D&O insurance? One month ago today, the German Whistleblower Protection Act came into force. Since July 2, 2023, not only companies with more than 50 employees, but also fund managers or ManCos (capital management companies pursuant to Section 17 (1) of the German Investment Code) are obliged to set up and operate a whistleblower system, regardless (!) of the number of employees. As of December 2

Read more "
Risk Partners

13th Hamburg Financial Lines Forum

Risk Partners at the Financial Lines Forum 13th Hamburg Financial Lines Forum. On October 12 and 13, 2023, the 13th Hamburg Financial Lines Forum took place with the participation of Risk Partners, a traditional event that once again served as a platform for the exchange of current trends. The program began with an overview of current developments and the handling of claims in financial lines, presented by Gabriele Schreiber-Sahin and Michael Hendricks. Dr. Oliver Sieg then shed light on directors' and officers' liability and the

Read more "
Life Sciences

Cyber Risks: Case Study Evotec

Last year, more than 10 percent of German companies were affected by an IT security incident, with the proportion rising due to cyber attacks. Biotechnology is not excluded either. It is possible to learn from the Evotec case. It is about successful cyber attacks or other incidents that are important for security, such as acts of sabotage or hardware theft. According to a representative Ipsos survey conducted on behalf of the TÜV association among 501 companies with more than ten employees. According to the TÜV

Read more "
Life Sciences

St. Gallen study: USD 6 billion per drug

HSG St. Gallen: Drug costs USD 6.16 billion on average. Are the days of new drugs costing less than USD 1 billion over? There were figures in the industry that spoke of USD 700-1,000 million as the cost of developing a new drug. A study by the University of St. Gallen covering the period 2001-2020 found that the cost of developing new drugs has risen dramatically. It was estimated that the cost of developing a new drug now stands at

Read more "